When making health decisions, it’s important to look at the best available evidence. A large, real-world study of more than 28 million adults aged 18–59 examined long-term outcomes after receiving an mRNA COVID-19 vaccine.
What the Study Found
In this research published in JAMA Network Open, investigators followed vaccinated and unvaccinated adults for up to four years after their first dose of an mRNA COVID-19 vaccine.
Here’s what they observed:
Understanding Risk and Benefit
Every medical choice carries some risk, whether someone chooses to get vaccinated or not. The goal is to choose the option associated with the lowest overall risk for each person.
Across large studies like this one, there is currently no evidence that mRNA COVID-19 vaccines increase the risk of death compared with remaining unvaccinated. In fact, vaccinated individuals in this analysis had lower all-cause mortality over four years.
Addressing Specific Risk Groups
Some rare side effects have been documented with mRNA vaccines, including myocarditis (inflammation of the heart muscle). For example, young males (<40 years) may have a slightly increased short-term risk of myocarditis after a second mRNA vaccine dose compared with their risk from COVID-19 infection itself. However, when weighing overall outcomes, vaccination still prevents many more serious health events.
For every one million males ages 12–29 receiving a second mRNA dose:
Latest Vaccine Formulations
Newer vaccine doses, such as the updated Moderna “Nextspike” formulation, use lower doses than the original vaccines, which may further reduce side-effect risks while maintaining strong immune protection.
Bottom Line
This study supports what other evidence has shown:
Have questions about your health or vaccines?
Learn more about our services and request an appointment to talk with a provider. Complete the form below to get started with a complimentary Meet & Greet session with our concierge providers, or call our office at 480.860.5500.